Journal
EXPERT REVIEW OF VACCINES
Volume 6, Issue 5, Pages 761-772Publisher
FUTURE DRUGS LTD
DOI: 10.1586/14760584.6.5.761
Keywords
adjuvant; antibody; immunotherapy; ISCOMATRIX; t-cell; vaccine
Categories
Ask authors/readers for more resources
The ISCOMATRIX (TM) adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as both CD4(+) and CD8(+) T cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have been evaluated in clinical trials. The results of these completed and ongoing studies indicate that the ISCOMATRIX adjuvant is safe and generally well tolerated and increases the vaccine immune responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available